Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Faecal occult blood screening for colorectal cancer: is it cost‐effective?

Faecal occult blood screening for colorectal cancer: is it cost‐effective? Recently published evidence from two large‐scale clinical trials conducted in England and in Denmark suggests that faecal occult blood screening for colorectal cancer significantly reduces mortality. However, before screening can be advocated as part of national health policy, its cost‐effectiveness must be demonstrated. The English screening trial has been the subject of a detailed economic evaluation over the past 10 years. In this paper, cost‐effectiveness estimates of screening are presented, based on cost and outcome data combined in a mathematical model developed from the trial's clinical findings. The estimates of cost per quality‐adjusted life‐year gained from colorectal cancer screening show the procedure to be of similar cost‐effectiveness to breast cancer screening in the short term. Over the longer term, however, the estimates for colorectal cancer screening appear superior. © 1998 John Wiley & Sons, Ltd. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Health Economics Wiley

Faecal occult blood screening for colorectal cancer: is it cost‐effective?

Loading next page...
 
/lp/wiley/faecal-occult-blood-screening-for-colorectal-cancer-is-it-cost-XQHz0d9sBo

References (29)

Publisher
Wiley
Copyright
Copyright © 1998 John Wiley & Sons, Ltd.
ISSN
1057-9230
eISSN
1099-1050
DOI
10.1002/(SICI)1099-1050(199802)7:1<21::AID-HEC306>3.0.CO;2-9
Publisher site
See Article on Publisher Site

Abstract

Recently published evidence from two large‐scale clinical trials conducted in England and in Denmark suggests that faecal occult blood screening for colorectal cancer significantly reduces mortality. However, before screening can be advocated as part of national health policy, its cost‐effectiveness must be demonstrated. The English screening trial has been the subject of a detailed economic evaluation over the past 10 years. In this paper, cost‐effectiveness estimates of screening are presented, based on cost and outcome data combined in a mathematical model developed from the trial's clinical findings. The estimates of cost per quality‐adjusted life‐year gained from colorectal cancer screening show the procedure to be of similar cost‐effectiveness to breast cancer screening in the short term. Over the longer term, however, the estimates for colorectal cancer screening appear superior. © 1998 John Wiley & Sons, Ltd.

Journal

Health EconomicsWiley

Published: Feb 1, 1998

There are no references for this article.